{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:38:26Z","timestamp":1781653106053,"version":"3.54.5"},"reference-count":107,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2017,7,31]],"date-time":"2017-07-31T00:00:00Z","timestamp":1501459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/about_us\/legal\/notices"}],"funder":[{"name":"European Renal Association-European Dialysis and Transplantation Association"},{"name":"ERA-EDTA"},{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]},{"name":"European Union\u2019s","award":["7. FP, REDDSTAR No. 305736"],"award-info":[{"award-number":["7. FP, REDDSTAR No. 305736"]}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020","doi-asserted-by":"publisher","award":["NEPHSTROM No. 634086"],"award-info":[{"award-number":["NEPHSTROM No. 634086"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,8,1]]},"DOI":"10.1093\/ndt\/gfx219","type":"journal-article","created":{"date-parts":[[2017,5,23]],"date-time":"2017-05-23T07:08:53Z","timestamp":1495523333000},"page":"1292-1304","source":"Crossref","is-referenced-by-count":21,"title":["The diabetes pandemic suggests unmet needs for \u2018CKD with diabetes\u2019 in addition to \u2018diabetic nephropathy\u2019\u2014implications for pre-clinical research and drug testing"],"prefix":"10.1093","volume":"33","author":[{"given":"Lidia","family":"Anguiano G\u00f3mez","sequence":"first","affiliation":[{"name":"Medizinische Klinik und Poliklinik IV, Klinikum der Universit\u00e4t M\u00fcnchen, Munich, Germany"},{"name":"Department of Nephrology, Hospital del Mar-IMIM, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutian","family":"Lei","sequence":"additional","affiliation":[{"name":"Medizinische Klinik und Poliklinik IV, Klinikum der Universit\u00e4t M\u00fcnchen, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satish","family":"Kumar Devarapu","sequence":"additional","affiliation":[{"name":"Medizinische Klinik und Poliklinik IV, Klinikum der Universit\u00e4t M\u00fcnchen, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Joachim","family":"Anders","sequence":"additional","affiliation":[{"name":"Medizinische Klinik und Poliklinik IV, Klinikum der Universit\u00e4t M\u00fcnchen, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,7,31]]},"reference":[{"key":"key\n\t\t\t\t20180801035942_gfx219-B1","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/ki.2012.428","article-title":"Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach","volume":"83","author":"Gadegbeku","year":"2013","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B2","doi-asserted-by":"crossref","first-page":"e87877","DOI":"10.1172\/jci.insight.87877","article-title":"Systems biology analysis reveals role of MDM2 in diabetic nephropathy","volume":"1","author":"Saito","year":"2016","journal-title":"JCI Insight"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B3","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1097\/00004872-199508000-00010","article-title":"Angiotensin II receptor blockade in TGR(mREN2)27: effects of renin-angiotensin-system gene expression and cardiovascular functions","volume":"13","author":"B\u00f6hm","year":"1995","journal-title":"J Hypertens"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B4","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","article-title":"Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial","volume":"372","author":"Mann","year":"2008","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B5","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1056\/NEJMoa042274","article-title":"Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy","volume":"351","author":"Barnett","year":"2004","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B6","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1681\/ASN.2006050423","article-title":"Glomerular localization and expression of angiotensin-converting enzyme 2 and angiotensin-converting enzyme: implications for albuminuria in diabetes","volume":"17","author":"Ye","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B7","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1111\/j.1745-7254.2007.00541.x","article-title":"Effect of telmisartan on expression of protein kinase C-\u03b1 in kidneys of diabetic mice 1","volume":"28","author":"Yao","year":"2007","journal-title":"Acta Pharmacol Sin"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B8","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1254\/jphs.12031FP","article-title":"Add-on aliskiren elicits stronger renoprotection than high-dose valsartan in type 2 diabetic KKAy mice that do not respond to low-dose valsartan","volume":"119","author":"Lei","year":"2012","journal-title":"J Pharmacol Sci"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B9","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa1001121","article-title":"Effect of valsartan on the incidence of diabetes and cardiovascular events","volume":"362","author":"NAVIGATOR Study Group","year":"2010","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B10","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1161\/01.CIR.0000024416.33113.0A","article-title":"Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect","volume":"106","author":"Viberti","year":"2002","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B11","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1042\/CS20130223","article-title":"Valsartan slows the progression of diabetic nephropathy in db\/db mice via a reduction in podocyte injury, and renal oxidative stress and inflammation","volume":"126","author":"Zhou","year":"2014","journal-title":"Clin Sci"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B12","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1097\/01.ASN.0000062961.76776.C1","article-title":"Anti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model","volume":"14","author":"Nangaku","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B13","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1007\/s00125-011-2325-z","article-title":"Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study","volume":"54","author":"Imai","year":"2011","journal-title":"Diabetologia"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B14","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1159\/000452588","article-title":"Olmesartan prevents microalbuminuria in db\/db diabetic mice through inhibition of angiotensin II\/p38\/SIRT1-induced podocyte apoptosis","volume":"41","author":"Gu","year":"2016","journal-title":"Kidney Blood Press Res"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B15","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1056\/NEJMoa1007994","article-title":"Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes","volume":"364","author":"Haller","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B16","first-page":"59","volume-title":"Jpn J Pharmacol","author":"Yotsumoto","year":"1997"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B17","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","article-title":"Combined angiotensin inhibition for the treatment of diabetic nephropathy","volume":"369","author":"Fried","year":"2013","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B18","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.lfs.2004.01.022","article-title":"Losartan ameliorates progression of glomerular structural changes in diabetic KKAy mice","volume":"75","author":"Sasaki","year":"2004","journal-title":"Life Sci"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B19","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa0708379","article-title":"Aliskiren combined with losartan in type 2 diabetes and nephropathy","volume":"358","author":"Parving","year":"2008","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B20","first-page":"F1448","volume-title":"Am J Physiol Renal Physiol","author":"Gagliardini","year":"2009"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B21","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B22","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ejphar.2014.10.021","article-title":"Combination therapy with spironolactone and candesartan protects against streptozotocin-induced diabetic nephropathy in rats","volume":"744","author":"Hofni","year":"2014","journal-title":"Eur J Pharmacol"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B23","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1136\/bmj.321.7274.1440","article-title":"Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the Candesartan And Lisinopril Microalbuminuria (CALM) study","volume":"321","author":"Mogensen","year":"2000","journal-title":"BMJ"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B24","first-page":"1405924","article-title":"Irbesartan ameliorates diabetic nephropathy by suppressing the RANKL-RANK-NF-\u03baB pathway in type 2 diabetic db\/db mice","volume":"2016","author":"Chen","year":"2016","journal-title":"Mediators Inflamm"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B25","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B26","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes","volume":"345","author":"Parving","year":"2001","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B27","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1161\/HYPERTENSIONAHA.107.108845","article-title":"Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats","volume":"52","author":"Feldman","year":"2008","journal-title":"Hypertension"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B28","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","article-title":"Cardiorenal end points in a trial of aliskiren for type 2 diabetes","volume":"367","author":"Parving","year":"2012","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B29","first-page":"2398","volume-title":"Diabetologia","author":"Kelly","year":"2007"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B30","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1097\/HJH.0b013e328338bb11","article-title":"Aliskiren enhances protective effects of valsartan against type 2 diabetic nephropathy in mice","volume":"28","author":"Dong","year":"2010","journal-title":"J Hypertens"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B31","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1093\/ndt\/gfp724","article-title":"Sulodexide ameliorates early but not late kidney disease in models of radiation nephropathy and diabetic nephropathy","volume":"25","author":"Rossini","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B32","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1681\/ASN.2011040378","article-title":"Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy","volume":"23","author":"Packham","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B33","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1097\/01.ASN.0000014254.87188.E5","article-title":"Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial","volume":"13","author":"Gambaro","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B34","doi-asserted-by":"crossref","first-page":"e54501","DOI":"10.1371\/journal.pone.0054501","article-title":"Sulodexide decreases albuminuria and regulates matrix protein accumulation in C57BL\/6 mice with streptozotocin-induced type 1 diabetic nephropathy","volume":"8","author":"Yung","year":"2013","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B35","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s00125-009-1540-3","article-title":"The endothelin receptor antagonist avosentan ameliorates nephropathy and atherosclerosis in diabetic apolipoprotein E knockout mice","volume":"53","author":"Watson","year":"2010","journal-title":"Diabetologia"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B36","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1681\/ASN.2009060593","article-title":"Avosentan for overt diabetic nephropathy","volume":"21","author":"Mann","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B37","first-page":"F808","volume-title":"Am J Physiol Renal Physiol","author":"Zoja","year":"2013"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B38","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1056\/NEJMoa1306033","article-title":"BEACON Trial Investigators. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease","volume":"26369","author":"de Zeeuw","year":"2013","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B39","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJMoa1105351","article-title":"Bardoxolone methyl and kidney function in CKD with type 2 diabetes","volume":"365","author":"Pergola","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B40","first-page":"F1438","volume-title":"Am J Physiol Renal Physiol","author":"Chin","year":"2013"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B41","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1755-1536-4-4","article-title":"Cooperative interaction of CTGF and TGF-\u03b2 in animal models of fibrotic disease","volume":"4","author":"Wang","year":"2011","journal-title":"Fibrogenesis Tissue Repair"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B42","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.2215\/CJN.09321209","article-title":"Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuria","volume":"5","author":"Adler","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B43","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s00125-017-4215-5","article-title":"Combined NOX1\/4 inhibition with GKT137831 in mice provides dose-dependent reno- and atheroprotection even in established micro- and macrovascular disease","volume":"60","author":"Gray","year":"2017","journal-title":"Diabetologia"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B44"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B45","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S0006-291X(02)02708-0","article-title":"Reversibility of established diabetic glomerulopathy by anti-TGF-beta antibodies in db\/db mice","volume":"300","author":"Chen","year":"2003","journal-title":"Biochem Biophys Res Commun"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B46"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B47","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1097\/01.ASN.0000074238.61967.B7","article-title":"Add-on anti-TGF-beta antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat","volume":"14","author":"Benigni","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B48","doi-asserted-by":"crossref","first-page":"e30555","DOI":"10.1371\/journal.pone.0030555","article-title":"Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models","volume":"7","author":"Liang","year":"2012","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B49","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S0140-6736(13)60683-2","article-title":"Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52\u2009week results from a randomised, double-blind, phase 3 non-inferiority trial","volume":"382","author":"Cefalu","year":"2013","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B50","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s12933-014-0148-1","article-title":"Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice","volume":"13","author":"Lin","year":"2014","journal-title":"Cardiovasc Diabetol"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B51","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B52","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1681\/ASN.2009070721","article-title":"Mouse models of diabetic nephropathy","volume":"20","author":"Brosius","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B53","first-page":"83","article-title":"Intercapillary lesions in the glomeruli of the kidney","volume":"12","author":"Kimmelstiel","year":"1936","journal-title":"Am J Pathol"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B54","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s00125-009-1268-0","article-title":"Is hyperfiltration associated with the future risk of developing diabetic nephropathy? A meta-analysis","volume":"52","author":"Magee","year":"2009","journal-title":"Diabetologia"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B55","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1056\/NEJM199807093390202","article-title":"Reversal of lesions of diabetic nephropathy after pancreas transplantation","volume":"339","author":"Fioretto","year":"1998","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B56","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus","volume":"329","author":"The Diabetes Control and Complications Trial Research Group","year":"1993","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B57","doi-asserted-by":"crossref","DOI":"10.1053\/j.ajkd.2016.11.018","article-title":"Diabetes control and the risks of ESRD and mortality in patients with CKD","author":"Navaneethan","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B58","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S0272-6386(99)70035-1","article-title":"End-stage renal failure in type 2 diabetes: a medical catastrophe of worldwide dimensions","volume":"34","author":"Ritz","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B59","doi-asserted-by":"crossref","DOI":"10.1111\/dme.13324","article-title":"Incidence of chronic kidney disease among people with diabetes: a systematic review of observational studies","author":"Koye","year":"2017","journal-title":"Diabet Med"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B60","doi-asserted-by":"crossref","first-page":"e0171027","DOI":"10.1371\/journal.pone.0171027","article-title":"Estimation of chronic kidney disease incidence from prevalence and mortality data in American Indians with type 2 diabetes","volume":"12","author":"Vijayakumar","year":"2017","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B61","doi-asserted-by":"crossref","DOI":"10.1016\/j.nephro.2016.07.453","article-title":"Ten-years trends in renal replacement therapy for end-stage renal disease in mainland France: lessons from the French Renal Epidemiology and Information Network (REIN) registry","author":"Vigneau","year":"2017","journal-title":"N\u00e9phrologie Th\u00e9rapeutique"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B62","doi-asserted-by":"crossref","first-page":"998","DOI":"10.3390\/jcm4050998","article-title":"Renal biopsy in type 2 diabetic patients","volume":"4","author":"Espinel","year":"2015","journal-title":"J Clin Med"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B63","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1001\/jama.2017.0686","article-title":"Association of type 1 diabetes vs type 2 diabetes diagnosed during childhood and adolescence with complications during teenage years and young adulthood","volume":"317","author":"Dabelea","year":"2017","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B64","first-page":"1","article-title":"The substantial loss of nephrons in healthy human kidneys with aging","volume":"28","author":"Denic","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B65","doi-asserted-by":"crossref","first-page":"3162","DOI":"10.1681\/ASN.2014080752","article-title":"Glomerular aging and focal global glomerulosclerosis: a podometric perspective","volume":"26","author":"Hodgin","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B66","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/nrneph.2012.19","article-title":"Glomerular hyperfiltration: definitions, mechanisms and clinical implications","volume":"8","author":"Helal","year":"2012","journal-title":"Nat Rev Nephrol"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B67","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.kint.2016.01.023","article-title":"An autopsy study suggests that diabetic nephropathy is underdiagnosed","volume":"90","author":"Klessens","year":"2016","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B68","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nrneph.2016.191","article-title":"Kidney disease and obesity: epidemiology, mechanisms and treatment","volume":"13","author":"C\u00e2mara","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B69","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1681\/ASN.2016060666","article-title":"Glomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment","volume":"28","author":"Tonneijck","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B70","first-page":"2096","article-title":"Clinical implications of basic research nephron protection in diabetic kidney disease","volume-title":"N Engl J Med","author":"Anders","year":"2016"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B71","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1146\/annurev-med-051013-110046","article-title":"The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus","volume":"66","author":"Vallon","year":"2015","journal-title":"Annu Rev Med"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B72","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1146\/annurev-physiol-020911-153333","article-title":"Renal function in diabetic disease models: the tubular system in the pathophysiology of the diabetic kidney","volume":"74","author":"Vallon","year":"2012","journal-title":"Annu Rev Physiol"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B73","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1159\/000187475","article-title":"Prevalence of glomerular hyperfiltration and nephromegaly in normo- and microalbuminuric type 2 diabetic patients","volume":"65","author":"Gragnoli","year":"1993","journal-title":"Nephron"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B74","first-page":"250","article-title":"Role of podocyte damage in the pathogenesis of glomerulosclerosis and tubulointerstitial lesions: findings in the growth hormone transgenic mouse model of progressive nephropathy","volume":"85","author":"Wanke","year":"2001","journal-title":"Verh Dtsch Ges Pathol"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B75","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1681\/ASN.2005050488","article-title":"Podocyte hypertrophy, \u2018adaptation\u2019, and \u2018decompensation\u2019 associated with glomerular enlargement and glomerulosclerosis in the aging rat: prevention by calorie restriction","volume":"16","author":"Wiggins","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4239\/wjd.v3.i1.1","article-title":"Renal hyperfiltration related to diabetes mellitus and obesity in human disease","volume":"3","author":"Sasson","year":"2012","journal-title":"World J Diabetes"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B77","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/ki.2011.404","article-title":"Glomerular hyperfiltration and increased glomerular filtration surface are associated with renal function decline in normo- and microalbuminuric type 2 diabetes","volume":"81","author":"Moriya","year":"2012","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B78","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1146\/annurev.pathol.4.110807.092150","article-title":"A glimpse of various pathogenetic mechanisms of diabetic nephropathy","volume":"6","author":"Kanwar","year":"2011","journal-title":"Annu Rev Pathol"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B79","first-page":"11: CD008143","article-title":"Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus","author":"Hemmingsen","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B80","first-page":"CD009122","article-title":"Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus","volume":"2","author":"Fullerton","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B81","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/1753-0407.12524","article-title":"American Diabetes Association Standards of Medical Care in Diabetes","volume":"9","author":"Marathe","year":"2017","journal-title":"J Diabetes"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B82","doi-asserted-by":"crossref","first-page":"e113459","DOI":"10.1371\/journal.pone.0113459","article-title":"A novel mouse model of advanced diabetic kidney disease","volume":"9","author":"Thibodeau","year":"2014","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B83","doi-asserted-by":"crossref","first-page":"e84683","DOI":"10.1371\/journal.pone.0084683","article-title":"Effect of insulin on ACE2 activity and kidney function in the non-obese diabetic mouse","volume":"9","author":"Riera","year":"2014","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B84","doi-asserted-by":"crossref","first-page":"F194","DOI":"10.1152\/ajprenal.00520.2013","article-title":"SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice","volume":"306","author":"Vallon","year":"2014","journal-title":"AJP Ren Physiol"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B85","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1242\/dmm.009266","article-title":"Accelerated renal disease is associated with the development of metabolic syndrome in a glucolipotoxic mouse model","volume":"5","author":"Martinez-Garcia","year":"2012","journal-title":"Dis Model Mech"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B86","doi-asserted-by":"crossref","first-page":"F1138","DOI":"10.1152\/ajprenal.00315.2002","article-title":"Diabetic kidney disease in the db\/db mouse","volume":"284","author":"Sharma","year":"2003","journal-title":"Am J Physiol Renal Physiol"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B87","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1440-1797.2006.00543.x","article-title":"Glomerular changes in the KK-Ay\/Ta mouse: a possible model for human type 2 diabetic nephropathy","volume":"11","author":"Ito","year":"2006","journal-title":"Nephrology"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B88","doi-asserted-by":"crossref","first-page":"F1008","DOI":"10.1152\/ajprenal.00597.2013","article-title":"Diabetic nephropathy in a nonobese mouse model of type 2 diabetes mellitus","volume":"306","author":"Mallipattu","year":"2014","journal-title":"Am J Physiol Renal Physiol"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B89","doi-asserted-by":"crossref","first-page":"e0153965","DOI":"10.1371\/journal.pone.0153965","article-title":"Beneficial effects of sarpogrelate and rosuvastatin in high fat diet\/streptozotocin-induced nephropathy in mice","volume":"11","author":"Kim","year":"2016","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B90","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1681\/ASN.2009121290","article-title":"BTBR Ob\/Ob mutant mice model progressive diabetic nephropathy","volume":"21","author":"Hudkins","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B91","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1681\/ASN.2006070798","article-title":"Endothelial nitric oxide synthase deficiency produces accelerated nephropathy in diabetic mice","volume":"17","author":"Zhao","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B92","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1093\/ndt\/gfn573","article-title":"Amelioration of diabetic tubulointerstitial damage in liver-type fatty acid-binding protein transgenic mice","volume":"24","author":"Kamijo-Ikemori","year":"2009","journal-title":"Nephrol Dial Transpl"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B93","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/ki.2010.287","article-title":"Angiotensin II overcomes strain-dependent resistance of rapid CKD progression in a new remnant kidney mouse model","volume":"78","author":"Leelahavanichkul","year":"2010","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B94","first-page":"116","article-title":"Dual blockade of the homeostatic chemokine CXCL12 and the proinflammatory chemokine CCL2 has additive protective effects on diabetic kidney disease. Am","volume":"179","author":"Darisipudi","year":"2011","journal-title":"J Pathol"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B95","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/498925","article-title":"Glomerulopathy in the KK.Cg-A(y)\/J mouse reflects the pathology of diabetic nephropathy","volume":"2013","author":"O\u2019Brien","year":"2013","journal-title":"J Diabetes Res"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B96","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1093\/ndt\/gfu411","article-title":"Diabetic nephropathy: landmark clinical trials and tribulations","volume":"31","author":"Chan","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B97","first-page":"351","article-title":"Tubular atrophy, interstitial fibrosis, and inflammation in type 2 diabetic db\/db mice. An accelerated model of advanced diabetic nephropathy","volume":"12","author":"Ninichuk","year":"2007","journal-title":"Eur J Med Res"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B98","doi-asserted-by":"crossref","first-page":"628","DOI":"10.2353\/ajpath.2008.070601","article-title":"Late onset of Ccl2 blockade with the Spiegelmer mNOX-E36\u20133\u2032PEG prevents glomerulosclerosis and improves glomerular filtration rate in db\/db mice","volume":"172","author":"Ninichuk","year":"2008","journal-title":"Am J Pathol"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B99","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.2353\/ajpath.2007.060937","article-title":"The role of interstitial macrophages in nephropathy of type 2 diabetic db\/db mice","volume":"170","author":"Ninichuk","year":"2007","journal-title":"Am J Pathol"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B100","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.2353\/ajpath.2010.090528","article-title":"Renal failure increases cardiac histone h3 acetylation, dimethylation, and phosphorylation and the induction of cardiomyopathy-related genes in type 2 diabetes","volume":"176","author":"Gaikwad","year":"2010","journal-title":"Am J Pathol"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B101","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1007\/s00125-009-1493-6","article-title":"Podocytes produce homeostatic chemokine stromal cell-derived factor-1\/CXCL12, which contributes to glomerulosclerosis, podocyte loss and albuminuria in a mouse model of type 2 diabetes","volume":"52","author":"Sayyed","year":"2009","journal-title":"Diabetologia"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B102","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/ki.2011.102","article-title":"An orally active chemokine receptor CCR2 antagonist prevents glomerulosclerosis and renal failure in type 2 diabetes","volume":"80","author":"Sayyed","year":"2011","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B103","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1093\/ndt\/gfp730","article-title":"Progressive glomerulosclerosis in type 2 diabetes is associated with renal histone H3K9 and H3K23 acetylation, H3K4 dimethylation and phosphorylation at serine 10","volume":"25","author":"Sayyed","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B104","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1681\/ASN.2015020208","article-title":"Cathepsin S cleavage of protease-activated receptor-2 on endothelial cells promotes microvascular diabetes complications","volume":"27","author":"Kumar","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B105","first-page":"167","article-title":"Effects of 5\/6 nephrectomy on renal function and blood pressure in mice","volume":"4","author":"Gava","year":"2012","journal-title":"Int J Physiol Pathophysiol Pharmacol"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B106","first-page":"307","article-title":"C-C motif-ligand 2 inhibition with emapticap pegol (NOX-E36) in type 2 diabetic patients with albuminuria","volume":"32","author":"Menne","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t20180801035942_gfx219-B107","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S2213-8587(15)00261-2","article-title":"The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial","volume":"3","author":"de Zeeuw","year":"2015","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/33\/8\/1292\/25198316\/gfx219.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,24]],"date-time":"2019-09-24T19:43:18Z","timestamp":1569354198000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/33\/8\/1292\/4056525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,31]]},"references-count":107,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2017,7,31]]},"published-print":{"date-parts":[[2018,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfx219","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,8]]},"published":{"date-parts":[[2017,7,31]]}}}